Key facts
- This page summarizes Karen L. Smith's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 May 2021, 16:30.
Karen L. Smith - 07 May 2021 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- EVP, Chief Medical Officer
- Issuer ticker
- EBS
- Reported as of
- 07 May 2021
- Net transaction value
- -$18,559
- SEC form
- 4
- Accepted by SEC
- 11 May 2021, 16:30:11 UTC
- Next SEC filing
- 14 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ S. Scott Lieberman, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Karen L. Smith filed Form 4 for Emergent BioSolutions Inc. (EBS) on 11 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$18,559.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EBS
transaction
Common Stock
Tax liability
- Transaction value
- $18,559
- Shares
- -305
- Change %
- -2.5%
- Price
- $60.85
- Shares after
- 11,888
- Date
- 07 May 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated.